Symeres published an article by Russell Thomas and Paul O'Shea discussing risk-based planning, scientific judgment, and interdisciplinary collaboration to help biotech companies keep programmes moving.
Published
Signal category
Research & Knowledge
Quote
“In this article, Paul O'Shea and I discuss how risk-based planning, scientific judgement and genuine collaboration across disciplines can help biotech companies keep programmes moving without losing sight of the overall objective.”
— Russell Thomas|Symeres team
Company
Symeres
Thinking ahead. Delivering above.
- Industry
- Biotechnology Research
- Location
- Nijmegen, NL
- Company size
- 508 employees
Symeres is a leading contract research, development and manufacturing organization (CDMO & CRO) supporting pharmaceutical and biotechnology companies across the full drug development lifecycle. From early discovery through to IND-enabling studies and GMP manufacturing, Symeres provides integrated expertise in medicinal chemistry, ADME-Tox, bioanalysis, solid-state chemistry, process development, CMC, and regulatory strategy and submission support. With transatlantic teams and over 30 years of scientific experience, Symeres helps accelerate the progression of small molecule drug candidates by combining deep technical knowledge with an open, nimble, and expert approach. The company works closely with clients to solve complex scientific challenges, de-risk development programs, and support efficient progression toward the clinic.
Founded 1987